(The 9th China International Import Expo) The China International Import Expo accelerates the implementation of innovation with its first show and promotes the advancement of health through science popularization

China News Service, Shanghai, November 10 (Li Qiuying, Li Jiajia) On November 10, the 9th China International Import Expo came to an end in Shanghai, but the innovation and science popularization in the medical and health sectors did not cool down as the exhibition drew to a close: visitors in the exhibition hall were still very interested, global innovative medicines and equipment were intensively launched, and health science popularization actions were implemented one after another, making the distance between "watching the exhibition" and "healthy living" within easy reach.

Takeda Pharmaceutical's innovative drug Aozeyue (Opreton Tablets) for the treatment of type 1 narcolepsy made its debut at the CIIE after being approved for marketing in China. It has become a new target innovative drug that was simultaneously developed and applied for simultaneously in the world and was the first to be approved in China. Dr. Liu Yan, President of Takeda China, said: "The consecutive successful hosting of the CIIE fully demonstrates China's firm commitment to promoting high-level opening up and promoting win-win cooperation. It also builds an important platform for global companies to share China's development opportunities."

Pengbo Boron Neutron Medical participated in the CIIE for the first time and exhibited the first BNCT (boron neutron capture therapy) complete treatment system at the CIIE, four of which were the core products for the first time in China. Photo courtesy of Pengbo Boron

Chinese innovation also stood on the world stage at this CIIE. At the Sanofi booth, China's independently developed Class 1 new drug Anxu (rovaxitinib tablets) made its world debut. As the world's first JAK/ROCK dual-target inhibitor, this drug targets myelofibrosis, which has long lacked anti-fibrosis treatments. Professor Huang Jian, deputy administrative director of the Hematology Department of the First Affiliated Hospital of Zhejiang University School of Medicine, said, "In recent years, China's original research innovations have continued to emerge in the field of blood. China's independent research and development breakthroughs represented by rovaxitinib have responded to the long-term lack of anti-fibrosis means in myelofibrosis, and also mark that China's innovation is leading the way of scientific innovation."

Pengbo Boron Neutron Medical participated in the exhibition for the first time and exhibited the first BNCT (boron neutron capture therapy) complete treatment system at the CIIE. Four core products were first launched in China. According to staff, this system has been put into clinical use in China: Hainan Boron Neutron Hospital, a subsidiary of Pengbo, has completed nearly 60 treatments as of October 2026. It is the first medical institution in China to use approved BNCT medical devices for clinical treatment.

In addition to innovative therapies, health science popularization through multi-party collaboration has become another main line. Boehringer Ingelheim and the National Center for Respiratory Medicine jointly launched the "Crossing the Sand Sea, Protecting Breathing - Dust Exposure and Respiratory Health Promotion" initiative, focusing on the respiratory health of people who have been exposed to dust and sand dust for a long time, and promoting early screening and diagnosis of interstitial pulmonary diseases. Professor Dai Huaping, deputy director of the National Center for Respiratory Medicine, said that the focus of prevention and treatment of respiratory diseases in my country is shifting from "treating the existing disease" to "treating the disease before it occurs", and hopes that the standardized respiratory health screening and early diagnosis and early management network will cover more people with high exposure to environmental dust.

Hypertension is a common chronic disease in China. Since early symptoms are often not obvious, some patients tend to ignore the risk of the disease. Some patients also reduce or stop taking medication after their blood pressure temporarily returns to normal, which affects the long-term stable control of blood pressure. At the event "Long-term compliance with standards, drip irrigation protection - multi-party discussions on grassroots hypertension science popularization". Wu Jing, director of the Center for Chronic and Non-Communicable Diseases Prevention and Control at the Chinese Center for Disease Control and Prevention, said, “Using the CIIE as a window to bring the actual needs of chronic disease management at the grassroots level into a broader public discussion will help explore science popularization paths that are closer to the grassroots and support long-term management of patients.”

IgA nephropathy is a progressive chronic kidney disease that has an insidious onset and requires long-term management. In the face of professional issues, the Internet and social media provide convenience for patients to understand the disease, but there may also be problems such as information fragmentation, one-sidedness and even inaccuracy, at a roundtable exchange on IgA nephropathy. Li Qing, director of the Department of Nephrology at TEDA Hospital of Tianjin University, said: "In recent years, IgA nephropathy patients have more and more channels for obtaining popular science information. This change has put forward higher requirements for the scientific nature and reliability of popular science information. Patients need to learn to identify the authenticity of popular science information and keep in mind the boundaries of use."

"Exquisite" and "Lung" - The First Lesson of HER2 Mutated Lung Cancer 2027 Public Welfare Science Popularization Action was successfully held during the CIIE. HER2-mutated non-small cell lung cancer accounts for about 2% to 4% of non-small cell lung cancer. It has the characteristics of strong tumor invasiveness, high risk of brain metastasis, and poor patient prognosis. It has long been regarded as one of the “difficult to treat subtypes” of many known driver genes. Chu Tianqing, chief physician of the Department of Respiratory Medicine at Shanghai Chest Hospital, said, "With the continuous development of precision treatment, the importance of standardized testing, diagnosis, treatment and long-term management has become increasingly prominent. How to identify HER2 mutations as early as possible through standardized testing, formulate appropriate treatment plans based on the patient's actual situation, and implement long-term disease management are important foundations for helping patients achieve long-term benefits."

At the Youth Scalp Health Science Forum, Zhu Quangang, a professor of pharmacy at Tongji University School of Medicine, reminded: "The stronger the cleaning power, the better the effect. Excessive cleaning will destroy the barrier and aggravate sensitivity and itching; you can clean it every day or every other day, gently rub your scalp with your fingertips and avoid scratching. If erythema, pustules, severe itching or recurring attacks occur, you should seek medical treatment in time."

The six-day event has come to an end, and the "two-way rush" between innovation and science popularization has just begun - global innovation continues to be implemented in China, and health consensus continues to extend to the public. Outside the exhibition hall is the real sequel of this event.